Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:18:27.354Z.
Calculation as of: 2026-10-06T16:18:27.354Z.
Quote observation: 2026-10-06T16:14:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5f06b8b41e0980caada53469fccf6de542fb6b04de3a821a907ddebd40a39f21
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
ProKidney Corp.
Market Cap
$536.32M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$533.68M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$539.58M
Operating Cash Flow Yield
3.63%
TTM Avg
3.98%
3Y Avg
3.57%
5Y Avg
3.57%
Market Cap
$540.42M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$524.44M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$520.39M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$549.33M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$550.37M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$519.25M
Operating Cash Flow Yield
N/A
TTM Avg
536.71%
3Y Avg
536.71%
5Y Avg
536.71%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProKidney Corp. (PROK) | $536.32M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $533.68M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $539.58M | 3.63% | 3.98% | 3.57% | 3.57% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $540.42M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $524.44M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $520.39M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $549.33M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $550.37M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $519.25M | N/A | 536.71% | 536.71% | 536.71% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $552.54M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
